Last reviewed · How we verify

William Sikov MD — Portfolio Competitive Intelligence Brief

William Sikov MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Brenda Cooper, MD · 1 shared drug class
  3. Bristol-Myers Squibb · 1 shared drug class
  4. EMS · 1 shared drug class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
  6. Glycotope GmbH · 1 shared drug class
  7. Grace Therapeutics Inc. · 1 shared drug class
  8. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for William Sikov MD:

Cite this brief

Drug Landscape (2026). William Sikov MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/william-sikov-md. Accessed 2026-05-16.

Related